X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
Investing in India? Get Equitymaster Research  
Indian equity markets remain firm 
(Fri, 19 Jul 01:30 pm) 
 
Indian equity markets continued to trade in the positive territory during the post noon trading session. Among the sectoral indices, the stocks from the IT sector and auto sector were leading among gainers, while capital goods and power stocks were the leading losers.

BSE-Sensex is up by 105 points and NSE-Nifty is trading up by 16 points. While BSE Mid Cap is trading down by 0.2%, BSE Small Cap index is trading up by 0.1%. The rupee is trading at 59.73 to the US dollar.

Majority of the automobile stocks are trading in the green with Force Motors and Hero MotoCorp being the biggest gainers. As per a leading financial daily, Ashok Leyland is expanding its portfolio in the defence segment by launching its Super Stallion range of vehicles in the domestic and overseas markets. The Super Stallion is a significantly bigger platform. Typically, Stallion is 230 HP, and Super Stallion is 360-400 HP. Ashok Leyland has established a new company called Ashok Leyland Defence System Ltd to foray into the defence sector. The company has a partnership for gun mounted systems and also has a platform for short missile systems. As per the company, it is the largest private supplier to the armed forces in India with its Ashok Leyland Stallion. Ashok Leyland stock is trading marginally down.

Indian pharma stocks are trading mixed with Aurobindo and Sun Pharma witnessing maximum selling pressure, while Orchid Chemicals and Piramal Enterprises are the top gainers. As per a financial daily, while Ranbaxy holds 180-days exclusivity on Diovan, it is awaiting approval from the USFDA (United States Food and Drug Administration) to launch the drug. However, Ranbaxy's delay in launch has been positive for the innovator Novartis. This is because, once Ranbaxy launches the drug, the innovator will witness sharp fall in its revenues of the said brand. Reportedly, the Swiss based company believes the generics for Diovan are not expected atleast till September 2013. This signifies that Ranbaxy's launch could further get delayed till the said time period. Ranbaxy was trading down by 1.2%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives  RSS
Read the latest Market Commentary
 
BSE-30
 

 
Go
 

Equitymaster requests your view! Post a comment on "Indian equity markets remain firm". Click here!

  
 

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Jul 27, 2017 12:07 PM

S&P BSE HEALTHCARE 5-YR ANALYSIS

COMPARE COMPANY

MARKET STATS